Uncovering the underlying mechanisms of Compound Yuxingcao Mixture in the treatment of COVID-19 based on network pharmacology

Xiaoyue Chen  
Guizhou University

Yongqiang Zhang  
Tsinghua University

Dongbo Yuan  
Guizhou Provincial People's Hospital

Bin Hu  
Guizhou Provincial People's Hospital

Guohua Zhu  
Guizhou Provincial People's Hospital

Wei Wang  
Guizhou Provincial People's Hospital

jianguo zhu (✉ jimezhang11@163.com)  
Guizhou Provincial People's Hospital  https://orcid.org/0000-0003-2410-2792

Research

Keywords: network pharmacology, COVID-19, Compound Yuxingcao Mixture, inflammatory response, mechanism

DOI: https://doi.org/10.21203/rs.3.rs-32916/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background and objective: The novel coronavirus named COVID-19 emerged in Wuhan, China in December, 2019 and has spread rapidly in China and around the world. The traditional Chinese medicine Compound Yuxingcao Mixture (CYM) has been recommended in recent editions of the national guideline while the underlying mechanisms are still unclear. In this study, we analyzed the effectiveness and potential mechanisms of CYM on COVID-19 based on network pharmacology and molecular docking approach.

Methods: The active ingredients and potential targets of CYM were screened using TCMSP and STITCH databases. Genes related severe acute respiratory syndromes (SARS) and Middle East respiratory syndrome (MERS) were queried on the DisGeNET and MalaCards databases. CYM-COVID-19 common target protein interaction network was established by STRING database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to generate the relative pathways based on KOBAS databases. In addition, the possible binding site of screened compounds were also predicted by Autodock vina software.

Results: A total of 103 active ingredients and 205 putative targets were screened from CYM, of which 32 overlapped with the targets of COVID-19 and were considered therapeutic targets. The analysis of the network diagram demonstrated that the CYM activity of ingredients of quercetin, luteolin, β-sitosterol and kaempferol may play a crucial role in treating COVID-19 by regulating TNF, IL-6, IL-1β, etc. The analysis of molecular binding energy showed that β-sitosterol had the lowest binding energy with COVID-19 3CLpro (-8.63 kJ/mol). GO and KEGG enrichment analysis revealed that these targets were closely associated with inflammatory responses and immune defense processes.

Conclusion: In summary, our study identified the potential mechanisms and targets of CYM for the prevention of COVID-19, providing directions for further clinical research.

Introduction

Since December 2019, the large-scale spread of the new coronavirus disease (COVID–19), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV–2), is a major epidemiological event[1]. As of April 14, 2020, COVID–19 has affected more than 1,948,617 patients in 210 countries and regions around the world, resulting in approximately 121,846 deaths worldwide[2, 3]. Since there are no effective control measures, the World Health Organization (WHO) eventually requested member countries to expand their emergency response mechanisms to find new vaccines and effective drugs[4].

Traditional Chinese medicine (TCM), as a core component of the national healthcare system, has been recommended in recent editions of the national guideline for the treatment of COVID–19[5]. COVID–19 belongs to the category of “pestilence” in TCM and is named “pulmonary pestilence”. Clinically, it has radiological characteristics of pneumonia, and presenting as fever and respiratory symptoms[6]. Subsequently, the Sichuan Provincial Health Commission recommended the Chinese patent medicine of Compound Yuxingcao Mixture (CYM) for clinical treatment[7]. This prescription consists of
*Houttuyniae Herba, Isatidis Radix, Scutellariae Radix, Lonicerae Japonicae Flos, Forsythiae Fructus.* Among them, *Houttuyniae Herba* is regarded as sovereign medicine which has the functions of clearing heat and detoxification, diuresis and dehumidification\(^\text{(8, 9)}\) [8, 9]. The CYM has been used in the clinical treatment of COVID–19 and achieved expected results, but its underlying mechanisms remains to be clarified.

Network pharmacology is an interactive network based on the theory of system biology, including cheminformatics, bioinformatics, network biology and pharmacology. It clearly reveals the underlying mechanisms of active ingredients acting on human body by constructing drug-active ingredient-target-disease network, which is consistent with the general view of TCM. The purpose of this study is to explore the underlying mechanism of CYM on COVID–19 disease through network pharmacology, drug targeting interaction database and biological analysis methods. Our flowchart is shown in Figure 1.

**Materials And Methods**

**Construction of the herb-property-flavor-meridian tropism network for CYM prescription**

The five herbs in the CYM prescription, and the corresponding information about their TCM properties (warm, cold and neutral), flavors (sweet, bitter and pungent) and meridian tropism (lung, heart, stomach, spleen, liver, gallbladder, large intestine and small intestine) were compiled from the Traditional Chinese Medicines Integrated Database (TCMID) (http://119.3.41.228:8000/tcmid/search/) and Encyclopedia of Traditional Chinese Medicine (ETCM) platform (http://www.tcmip.cn/ETCM/index.php/Home/Index/). A network of herb-property-flavor-meridian tropism was constructed using R package.

**Collection of active ingredients**

The active ingredients of CYM were collected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) platform (http://tcmspw.com/tcmsp.php). Oral bioavailability (OB) refers to the percentage of unmodified drugs that enter the circulatory system after oral administration. Drug likeness (DL) is a vague concept that refers to the similarity between compounds and known drugs. According to the relevant parameters of the pharmacokinetic properties, the active ingredients of CYM were screened using the OB% ≥ 30% and DL ≥ 0.18 as parameters\(^\text{(10, 11)}\) [10, 11].

**Screening of target genes for active ingredients**

The names and numbers of active ingredients obtained from the TCMSP database were gathered and retrieved on the PubChem database (https://pubchem.ncbi.nlm.nih.gov/), and the corresponding SMILE numbers were recorded as well. Subsequently, the following two databases DrugBank (http://www.drugbank.ca) and STITCH (http://stitch.embl.de/) were used to predict the target information.
of active ingredients. Finally, all the target information was standardized using UniProt (http://www.UniProt.org/).

**Screening of potential targets for COVID–19**

No data on COVID–19-related genes were available in the DisGeNET (https://www.disgenet.org/) and MalaCards (https://www.malacards.org/) databases in the present study. Because the new coronavirus is very similar to SARS-CoV and MERS-CoV, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) was used in our research to gather the target genes that may be related to the new coronavirus.

**PPI network construction**

To explain the interaction between target genes, the selected genes were uploaded to STRING database (http://string-db.org) to obtain the information of protein-protein interaction (PPI). In the present study, the species was set as *Homo sapiens*, the minimum required interaction score was set as medium confidence 0.400, then the remaining parameters remained the default settings. Subsequently, the information of PPIs was downloaded and visualized using Cytoscape 3.7.1. In all nodes, the size and color of the nodes were used as the criteria for screening hub genes.

**Drug-active ingredient-target network construction**

A Venn diagram was used to visualize the amount of overlap between the genes related to the CYM ingredients and COVID–19-related genes. After removing the redundant genes, the drug-active ingredient-target network was constructed by cytoscape 3.7.1 software. In the network diagram, the nodes represent five traditional Chinese medicines, active ingredients, and therapeutic targets respectively. The edges in the network were used to connect drugs-active ingredients-therapeutic targets and the amount of edges were measured in degrees.

**Gene ontology and KEGG enrichment analysis of target genes**

To elucidate the potential biological function of CYM in the treatment of COVID–19, GO (Gene Ontology) functions and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis were performed. The gene list of targets were inputted into STRING (http://string-db.org) and KOBAS (http://kobas.cbi.pku.edu.cn/) to perform GO and pathway analysis. The $P$-value<0.05 were considered to be statistically significant, then the bubble plot of pathways were drawn via imageGP (http://www.ehbio.com/) platform.
Molecular docking

The protein COVID–19 3CL\textsuperscript{pro} (PDB ID:6LU7) required for docking was obtained from PDB (https://www.rcsb.org/) database. The AutoDockTools 1.5.6 software was used to remove water molecules, perform hydrogenation and calculate the charge of the protein. Finally, it was saved as pdbqt format file. The structure of small molecule ligands of the TCM that need to be docked were obtained from Pubmed (https://www.ncbi.nlm.nih.gov/Pubmed) and ZINC (https://zinc.docking.org/). Subsequently, the Autodock vina software was used for molecular docking (the parameters were set as num_modes = 10, energy_range = 4, exhaustiveness = 100).

Results

The herb-property-flavor-meridian tropism network for CYM prescription

Based on TCM theory, the five herbs in CYM were classified according to their property, flavor and meridian tropism (Table 1 and Figure 2). A network was constructed among elements of the TCM classification system (Table 1) and the five herbs of the CYM prescription via R software. The connection degree of lung, heart, stomach and small intestine is the highest in the meridian tropism group, and the corresponding connection values are four, three, two and two, respectively. Four herbs (Houttuyniae Herba, Scutellariae Radix, Lonicerae Japonicae Flos, Forsythiae Fructus) in CYM are associated with the lung meridian. Among the flavor group, the greatest degree of connection is bitter, with three degrees of association.

Screening potential targets of CYM

To identify the active compounds of CYM, two classical ADME parameters, OB\%\geq30\% and DL\geq0.18, were used for screening. Through mining the TCMSP, a total of 594 potential compounds were screened from five traditional Chinese medicines (Supplemental Tabel 1). After that, we inputted the molecular name and SMILE number of the active ingredients into the Drugbank and STITCH databases to obtain 151 and 80 putative targets of CYM, respectively. The putative targets included PTGS1, IL–6, JUN, TNF, IFNG, IL–2 and so on. Detailed information about the potential targets of CYM was shown in (Figure 3A, Supplemental Table 2).

The acquisition of known therapeutic targets for COVID–19

Genes related to COVID–19 were retrieved from the DisGeNET database and MalaCards database using the keywords “SARS” and “MERS”. In the study, a total of 260 known therapeutic targets were collected from DisGeNET database and 144 known therapeutic targets were collected from MalaCards database. After eliminating redundant targets, a total of 351 known therapeutic targets were collected (Figure 3B).
Then the potential targets in CYM was mapped to the COVID–19 targets to obtain 32 therapeutic genes using the ImageGP platform, and a Venn diagram was drawn (Figure 3C and Table 2).

**PPI networks construction and core genes screening**

PPI network was used to explore the function of diverse targets in CYM and COVID–19. A acquisition of 32 targets were inputted into the STRING database, the medium confidence score was set as 0.400 for further analysis, and then visualized by Cytoscape 3.7.1. There were 32 protein nodes and a total of 225 interactive connecting lines in the PPI network. The average node degree of freedom is 14.1, and the avg. local clustering coefficient is 0.758. Among all core targets, the bigger the deeper, the more important it is. Further analysis from cytoHubba revealed that the degree of tumor necrosis factor (TNF), interleukin 6 (IL–6) and interleukin 1β (IL–1β) is 30, 28 and 25 respectively, which were closely related to the inflammatory response (Figure 4).

**Drugs-Compounds-Targets network analysis**

To elucidate the potential mechanism of CYM in the treatment of COVID–19, we used Cytoscape 3.7.1 software to build the Drugs-Active compounds-Targets network. The hexagon nodes represent five traditional Chinese medicines, the ellipse nodes represent 103 active ingredients and the diamond nodes represent 32 overlapping targets for disease. The edges indicate that nodes can interact with each other. Further analysis of the network topology shows that the centralization and heterogeneity are 0.339 and 1.602 respectively, which indicates that the compound-target space has a tendency for certain compounds and targets. Therefore, the network contains some core ingredients with multi-targets, such as Quercetin (degree = 75), Luteolin (degree = 24), Beta-sitosterol (degree = 28), Wogonin (degree = 18), Acacetin (degree = 10), Kaempferol (degree = 24), which may play a crucial role in the treatment of COVID–19 (Figure 5).

**Gene ontology enrichment analysis**

To verify whether the 32 target genes are related to COVID–19, we entered the candidate targets into the STRING platform for GO functional enrichment and annotation. In the study, a total of 750 biological processes, 52 molecular functions, and 25 cellular components were obtained. The top 10 entries were selected based on false discovery rate (FDR) <0.05 and the number of enriched genes, and then visualized by Cytoscape (Figure 6). The X-axis indicates the number of enriched genes for the term, and the Y-axis indicates the GO term. The results demonstrated that the biological processes mainly involved response to stimulus (32 targets), cellular process (32 targets), biological regulation (30 targets) (Figure 6A, B); the molecular functions mainly involved Binding (31 targets), Protein binding (26 targets), Catalytic activity (17 targets) (Figure 6C, D); the cellular components mainly involved Intracellular (30 targets), Extracellular region (24 targets), Extracellular space (20 targets) (Figure 6E, F). The GO enrichment analysis results showed that the active compounds of CYM could participate in various cellular processes, so as to treat COVID–19.
The KEGG pathway enrichment analysis

The selected targets were inputted into KOBAS database to carry out pathway enrichment analysis. A total of 183 signaling pathways were obtained, and the top of 20 entries were screened according to the number of enriched targets (Figure 7A, B). The signaling pathways were listed as follows: Pathways in cancer, Inflammatory bowel disease (IBD), IL–17 signaling pathway, Chagas disease (American trypanosomiasis), AGE-RAGE signaling pathway in diabetic complications, C-type lectin receptor signaling pathway, Yersinia infection, Fluid shear stress and atherosclerosis, Tuberculosis, Cytokine-cytokine receptor interaction, Leishmaniasis, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Th17 cell differentiation, Jak-STAT signaling pathway, NOD-like receptor signaling pathway, Human cytomegalovirus infection, Pertussis, Toll-like receptor signaling pathway, TNF signaling pathway. These results suggest that the effective pharmacological ingredients in CYM may treat COVID–19 through alleviating inflammatory responses and enhancing immune pathways. The inflammatory bowel disease (IBD) and IL–17 signaling pathway, which play a crucial role in treating disease were annotated (Figure 7C, D).

Analysis of molecular docking and binding modes results

It is worth noting that we have made several milestone discoveries, including the crystal structure of 3CL\textsuperscript{pro}, which can serve as candidate molecular target for SARS therapy\cite{12}. To evaluate the targeting of several active ingredients in CYM to COVID–19 3CL\textsuperscript{pro}, we selected the top six ingredients with larger degrees from the network diagram for molecular docking and binding energy analysis (Table 3 and Figure 8). The binding energy of the core active ingredients of CYM are all less than $-5$ kJ/mol, of which the lowest binding energy of active compounds with COVID–19 3CL\textsuperscript{pro} is beta-sitosterol ($-8.63$ kJ/mol).

Discussion

From the perspective of TCM, the medication paradigm for the treatment of COVID–19 is based on a comprehensive and dialectical understanding of the pathological evolution of COVID–19. As the epidemic disease outbreak is urgent, serious and highly infectious, the pathogen is generally attributed to dampness toxin according to the main symptom characteristics of this disease\cite{13}. TCM deduces that COVID–19 is located in lung and closely related to stomach and spleen. Its pathological changes involve the heart, liver and kidney in the later stage\cite{14}. Dampness pathogen can slowly evolve into cold-dampness or dampness-heat, and it depends entirely on the patients’ body constitution. Clinical observation reveals that patients will present some symptoms of Qi and Yin deficiency\cite{15, 16}. Therefore, TCM recommends that the patients should gradually restore sufficient health Qi to dispel pathogen from the body, so that they will enter the recovery period. The CYM has the functions of clearing heat and detoxication, enhancing the body’s immunity, and stimulating the body’s immune defense system to indirectly exert anti-viral effects. Among them, \textit{Houttuyniae Herba} and \textit{Scutellariae Radix} is regarded as sovereign and assistant medicine respectively. And the rest are adjuvants, which cooperates with together to exert the efficacy.
In this study, the network pharmacology method was used to screen active ingredients in CYM, we obtained their target genes and established a visual network analysis of drugs-active ingredients-target genes. Preliminary analysis indicated that 103 potential active ingredients in CYM might play a crucial role in regulating 32 targets through multiple cellular processes mainly involved response to stimulus (32 targets), cellular process (32 targets), biological regulation (30 targets). Further analysis demonstrated that these 32 targets were roughly divided into three categories: inflammatory cytokines, mitogen-activated protein kinases and others. Among them, the inflammatory cytokines are mainly TNF, IL–6, IL–1β, CCL2, IL–10, IL–2, which concentrate on inflammatory responses. As reported, IL–6 is an important cytokine that initially expressed through the immune system in response to injurious or infectious processes(17) [17]. In the early stage, it activates the JAK/STAT signal pathway, and initiates B cell differentiation, plasma cell production and a series of acute reactions(18, 19) [18, 19]. The increase of IL–6 occurs early in the initiation of cellular stress and has a long duration, so it can be used as an indicator for the early diagnosis of acute infection as well as the severity and prognosis of infection(20) [20]. The Yi JH team analyzed 69 severe COVID–19 patients and found that the level of IL–6 in severe patients was significantly higher than in non-severe patients, which was closely related to the patients’ maximum temperature and CT results(21) [21].

According to the characteristics of network topology, the core nodes including Quercetin (degree = 75), Luteolin (degree = 24), Beta-sitosterol (degree = 28), Wogonin (degree = 18), Acacetin (degree = 10), Kaempferol (degree = 24) were screened in the network diagram, which might be the potential ingredients of CYM for the treatment of COVID–19. Since antiviral activity of some flavonoids is known, Jo et al applied a flavonoid library to probe inhibitory compounds against MERS-CoV 3C-like protease (3CLpro) and demonstrated that quercetin 3-β-D-glucoside had high efficiency on blocking the enzymatic activity of MERS-CoV 3CLpro, which was also confirmed independently using a tryptophan-based fluorescence method(22) [22]. In addition, several studies have demonstrated that quercetin produced its anti-inflammatory activity by acting on TLR4 and cytokines. In LPS-triggered signaling via TLR4, quercetin suppressed the nuclear factor of kappa light polypeptide gene enhancer in B degradation, and subsequently stimulated the phosphorylation of AKT and p38/MAPK in bone marrow-derived macrophages(23) [23]. In the present study, the results of molecular docking and binding energy analysis demonstrated that the selected CYM ingredients also had high binding degree with the active site of COVID–19 3CLpro in the virus (Figure 8).

Using the KEGG pathway enrichment tool, we can obtain some important pathways that may be regulated by the drugs studied in the process of treating diseases, thus helping us to understand the mechanisms of drugs in treating diseases. In this study, the selected targets were analyzed by KOBAS platform, and the top 20 entries were screened out including the inflammatory bowel disease (IBD), Jak-STAT signaling pathway, TNF signaling pathway and IL–17 signaling pathway, which demonstrated that CYM could indirectly exert anti-viral effect by enhancing the body’s immunity and stimulating the body’s immune defense system.

Conclusion
In summary, the network pharmacology method was used in our study to predict the therapeutic targets and underlying mechanisms of CYM in the treatment of COVID–19. Although the predicted results were consistent with recent researches, more clinical trials are warranted for our findings to be confirmed.

**Abbreviations**

CYM: Compound Yuxingcao Mixture; MERS: Middle East respiratory syndrome; SARS: severe acute respiratory syndromes; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; COVID–19: the new coronavirus disease; TCM: Traditional Chinese medicine; TCMID: Traditional Chinese Medicines Integrated Database; ETCM: Encyclopedia of Traditional Chinese Medicine; TCMSP: Traditional Chinese Medicine Systems Pharmacology; OB: Oral bioavailability; DL: Drug likeness; PPI: protein-protein interaction; TNF: tumor necrosis factor; IL–6: interleukin 6; IL–1β: interleukin 1β.

**Declarations**

**Author contributions**

J. G. Zhu conceived and designed the studies. X. Y. Chen and Y. Q. Zhang completed the data collection and analysis. All authors participated in drafting of the manuscript and revising it before final submission.

**Conflict of interest**

The authors declare that they have no conflicts of interest.

**Finding**

This work was supported by grants from The National Natural Science Foundation of China (81660426), the Science and Technology Project of Guizhou Province in 2017 ([2017]5803), The High-level innovative talent project of Guizhou Province in 2018 ([2018]5639), The Science and Technology Plan Project of Guiyang in 2019 ([2019]2–15), Science and Technology Plan Project of Guizhou Province in 2019 ([2019]1203).

**References**

1. Singhal T. A Review of Coronavirus Disease–2019 (COVID–19). Indian Journal of Pediatrics 2020;87(4):281–6.

2. Abd ET, Stockand JD. Recent progress and challenges in drug development against COVID–19 coronavirus (SARS-CoV–2) - an update on the status. Infection Genetics and Evolution 2020;83:104327.
3. Coronavirus Outbreak. Available at: https://www.worldometers.info/coronavirus/. Accessed 23 Feb 2020.

4. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID–19 - 11 March 2020. Geneva: World Health Organization; 2020.

5. Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID–19 treatment. Pharmacological Research 2020;155:104743.

6. Yang Z, Shi J, He Z, Lu Y, Xu Q, Ye C, Chen S, Tang B, Yin K, Lu Y, Chen X. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID–19) patients. Aging (Albany NY) 2020;12(7):6037–48.

7. QH W, X Q, TX Z, LF H, W L, J P. Analysis of Key Varieties and Rational Allocation of Traditional Chinese Medicine Resources Under COVID–19 Epidemic Situation. Chin J Exp Tradit Med Form 2020;p.1–7.(http://kns.cnki.net/kcms/detail/11.3495.R.20200410.1723.005.html).

8. Dai W, Hu L, Ji L, Li J, Bi K, Li Q. A Comprehensive Method for Quality Evaluation of Houttuyniae Herba by a Single Standard to Determine Multi-components, Fingerprint and HPTLC Method. Analytical Sciences 2015;31(6):535–41.

9. Zhu CS, Nie AZ, Zhang B, Lin ZJ. [Medication rules of Professor Zhang Bing in treatment of skin itching based on data mining]. Zhongguo Zhong Yao Za Zhi 2019;44(3):597–601.

10. Wang ZY, Jiang ZM, Xiao PT, Jiang YQ, Liu WJ, Liu EH. The mechanisms of baicalin ameliorate obesity and hyperlipidemia through a network pharmacology approach. European Journal of Pharmacology 2020;878:173103.

11. Zhao X, Hao J, Chen S. Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer. Evid Based Complement Alternat Med 2020;2020:6076572.

12. Serseg T, Benarous K, Yousfi M. Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMPro), molecular docking and SAR study. Curr Comput Aided Drug Des 2020.

13. Ho L, Chan K, Chung V, Leung TH. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID–19. European Journal of Integrative Medicine 2020:101116.

14. Zhang YS, Cong WH, Zhang JJ, Guo FF, Li HM. [Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus]. Zhongguo Zhong Yao Za Zhi 2020;45(6):1263–71.

15. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin JK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang YY, Wang XH. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4.
16. Luo E, Zhang D, Luo H, Liu B, Zhao K, Zhao Y, Bian Y, Wang Y. Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID–19): an empirical study from Wuhan, Hubei Province, China. Chin Med 2020;15:34.

17. Akkaya M, Kwak K, Pierce SK. B cell memory: building two walls of protection against pathogens. Nature Reviews Immunology 2020;20(4):229–38.

18. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389(10086):2328–37.

19. Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL–6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem 2020;28(5):115327.

20. Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. J Infect 2020.

21. Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, Cheng J, Zhang X, Zhao Y, Xia Z, Zhang L, Wu G, Yi J. The potential role of IL–6 in monitoring severe case of coronavirus disease 2019. medRxiv 2020(https://doi.org/10.1101/2020.03.01.20029769).

22. Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chemical Biology & Drug Design 2019;94(6):2023–30.

23. Kaneko M, Takimoto H, Sugiyama T, Seki Y, Kawaguchi K, Kumazawa Y.Suppressive effects of the flavonoids quercetin and luteolin on the accumulation of lipid rafts after signal transduction via receptors. Immunopharmacol Immunotoxicol 2008;30(4):867–82.

Table

### Table 1 Property, flavor and meridian tropism of herbs in CYM.

| Herb | Property | Flavor | Meridian tropism |
|------|----------|--------|------------------|
| Latin name | Acronym | Chinese name | Cold | Sweet | Bitter | Pungent | Lung | Stomach | Heart | Spleen | Gallbladder | Large Intestine | Small Intestine |
| Houttuynia Cordatae Herba | HH | Yuxingcao | ✓ | ✓ | ✓ |
| Scutellariae Radix | SR | Huangqin | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Isatidis Radix | IR | Banlangen | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lonicerae Japonicae Flos | LJF | Jinyinhua | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Forsythiae Fructus | FF | Lianqiao | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Total | 5 | 1 | 3 | 1 | 4 | 2 | 3 | 1 | 1 | 1 | 1 | 2 |

Table 2 Information of 32 therapeutic genes.
| Number | Gene name                                      | Gene symbol | Uniprot-ID |
|--------|-----------------------------------------------|-------------|------------|
| 1      | Prostaglandin G/H synthase 1                  | PTGS1       | P23219     |
| 2      | Tumor necrosis factor                         | TNF         | P01375     |
| 3      | Interleukin-6                                 | IL6         | P05231     |
| 4      | Transcription factor AP-1                     | JUN         | P05412     |
| 5      | C-C motif chemokine 2                         | CCL2        | P13500     |
| 6      | Beta-2 adrenergic receptor                    | ADRB2       | P07550     |
| 7      | Dipeptidyl peptidase IV                       | DPP4        | P27487     |
| 8      | Mitogen-activated protein kinase 14           | MAPK14      | Q16539     |
| 9      | Serum paraoxonase/arylesterase 1              | PON1        | P27169     |
| 10     | Thrombin                                      | F2          | P00734     |
| 11     | Acetylcholinesterase                          | ACHE        | P22303     |
| 12     | Mu-type opioid receptor                       | OPRM1       | P35372     |
| 13     | Myeloperoxidase                               | MPO         | P05164     |
| 14     | Mitogen-activated protein kinase 1            | MAPK1       | P28482     |
| 15     | Cathepsin D                                   | CTSD        | P07339     |
| 16     | Interferon gamma                              | IFNG        | P01579     |
| 17     | Interleukin-2                                 | IL2         | P60568     |
| 18     | Interleukin-1 beta                            | IL1B        | P01584     |
| 19     | Tissue-type plasminogen activator             | PLAT        | P00750     |
| 20     | Thrombomodulin                                | THBD        | P07204     |
| 21     | Tissue factor                                 | F3          | P13726     |
| 22     | Arachidonate 5-lipoxygenase                   | ALOX5       | P09917     |
| 23     | Heme oxygenase 1                              | HMOX1       | P09601     |
| 24     | Retinoblastoma-associated protein             | RB1         | P06400     |
| 25     | Superoxide dismutase [Cu-Zn]                  | SOD1        | P00441     |
| 26     | Epidermal growth factor receptor              | EGFR        | P00533     |
| 27     | Maltase-glucoamylase, intestinal              | MGAM        | O43451     |
| 28     | Signal transducer and activator of transcription 1-alpha/beta | STAT1 | P42224     |
| 29     | Interleukin-5                                 | IL5         | P05113     |
| MOL ID  | Name                      | CAS     | Structural Formula | Binding energy (kJ/mol) |
|---------|---------------------------|---------|--------------------|------------------------|
| MOL00006 | Luteolin                  | 491-70-3| ![Structural Formula](image1) | -7.16                  |
| MOL00098 | Quercetin                 | 73123-10-1| ![Structural Formula](image2) | -5.97                  |
| MOL00173 | Wogonin                   | 632-85-9| ![Structural Formula](image3) | -7.45                  |
| MOL00358 | Beta-sitosterol           | 83-46-5 | ![Structural Formula](image4) | -8.63                  |
| MOL00422 | Kaempferol                | 520-18-3| ![Structural Formula](image5) | -6.26                  |
| MOL00689 | Acacetin                  | 480-44-4| ![Structural Formula](image6) | -6.28                  |

**Table 3 Molecular docking results of key targets.**

**Figures**
Figure 1

The flowchart of a systematic network pharmacology-based strategy to explore the pharmacological mechanisms of CYM for the treatment of COVID-19.
Figure 2

The herb-property-flavor-meridian tropism network of the CYM prescription. The network indicates the interconnection of the five herbs in CYM and corresponding information about their TCM property (cold), flavors (sweet, bitter and pungent) and meridian tropisms (lung, stomach, heart, spleen, gallbladder, large intestine and small intestine). The herbs are linked to their assigned terms via colored ribbons. HH: Houttuyniae Herba; SR: Scutellariae Radix; IR: Isatidis Radix; LJF: Lonicerae Japonicae Flos; FF: Forsythiae Fructus.
The potential targets of CYM and the overlapping therapeutic target genes of COVID-19 were mapped in the Venn diagram. (A) A total of 151 and 80 putative targets of CYM were obtained from Drugbank and STITCH databases. (B) A total of 351 known therapeutic targets were collected from DisGeNET and MalaCards databases. (C) The 32 overlapping genes between the CYM and COVID-19.
Figure 4

Common target PPI network between CYM and COVID-19. The nodes represent target genes, and the connections represent the interaction between two targets. The bigger the deeper, the more important it is.
Figure 5

The drug-active ingredient-target network. The hexagon nodes represent traditional Chinese medicines, the ellipse nodes represent active ingredients and the diamond nodes represent overlapping targets for disease.
Figure 6
Gene ontology (GO) term enrichment for hub genes. (A,B) The top 10 entries of biological functional analysis of the core targets. (C,D) The top 10 entries of molecular function among candidate targets. (E,F) The top 10 entries of cellular component of the core targets. The X-axis indicates the number of enriched genes for the term, and the Y-axis indicates the GO term.

Figure 7

Signaling pathway enrichment analysis of the overlapping targets of CYM for COVID-19. (A,B) Representative wordcloud and bubble plots of the top 20 enrichment pathways of the core targets. (C,D) Distribution of the target genes of CYM on the predicted pathway. The red nodes are potential targets in 32 overlapping genes, while the blue nodes are relevant targets in the pathway.
Figure 8

Molecular docking analysis between the selected ingredients and COVID-19 3CLpro. (A,B,C,D,E,F) A ball&stick represents a compound and a cartoon chain represents the active site of COVID-19 3CLpro. (G,H,I,J,K,L) Schematic diagrams represented the 3CLpro binding site and proximate affinity of candidate compounds in CYM. Black dots: carbon atoms; blue dots: nitrogen atoms; red dots: oxygen atoms; green dotted lines: hydrogen bonds; red combs: amino acid residues.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalTable1.docx
- SupplementalTable2.docx